Compliance and Enforcement
Regulatory Activities
Clinical Investigators - Disqualification Proceedings
Return to Introductory Page
Name Center Status Date of status Date NIDPOE Issued Date NOOH Issued Link to NIDPOE Letter Link to NOOH Letter Doss, Jr., William L., MD
CDER
Disqualified
06/14/1979
11/15/1977
03/03/1978
Chaplan, Abraham A., MD
CDER
Disqualified
02/28/1979
Lamphier, Timothy A., MD
CDER
Disqualified
02/14/1979
Dalton, Fred C., MD
CDER
Disqualified
01/03/1979
10/18/1978
Kurland, Morton L., MD
CDER
Disqualified
11/06/1978
Savery, Francois, MD
CDER
Disqualified
10/06/1978
Close, John H., MD
CDER
Disqualified
07/19/1978
Schneyer, Jerome J., MD
CDER
Disqualified
04/16/1978
McCracken, Elbert, MD
CBER
Disqualified
05/03/1977
07/12/1976
10/27/1976
Froning, Edward C., MD
CDER
Disqualified
04/10/1976
07/31/1975
Rotstein, Jerome, MD
CDER
Disqualified
12/03/1975
Day, Phillip L., MD
CDER
Disqualified
08/28/1975
Balin, Howard, MD
CDER
Disqualified
03/19/1975
Dunlop, Edwin, MD
CDER
Reinstated
12/24/1970
Sobatka, Joseph H., MD
CDER
Disqualified
09/21/1970
Shubin, Harry, MD
CDER
Disqualified
03/16/1970
Rubin, Wallace, MD
CDER
Disqualified
03/13/1970
Carter, Charles, MD
CDER
Reinstated
07/29/1969
Lapolla, Anthony, MD
CDER
Disqualified
05/05/1969
Bender, Sheldon R., MD
CDER
Disqualified
02/17/1969
McHardy, Gordon, MD
CDER
Reinstated
01/27/1969
Splitter, Samuel, MD
CDER
Disqualified
07/29/1968
Lowe, Leo, MD
CDER
Disqualified
10/18/1966
Abruzzi, Jr., William A., MD
CDER
Disqualified
08/31/1966
Copelan, Herbert W., MD
CDER
Reinstated
08/19/1966
Kligman, Albert M., MD
CDER
Reinstated
08/19/1966
Cass, Leo, MD
CDER
Disqualified
12/15/1965
Roberts, Kathleen E., MD
CDER
Disqualified
11/24/1964
Robin, Bennett, MD
CDER
Disqualified
06/19/1964
Kumar, Anil, MD
CDER
Not Disqualified
05/02/2014
PDF
Prev
|
Next
|
1
|
2
|
3
|
4
|
[5]
|
First
|
Last
|
All
1. Under regulations in effect until 1987, investigators who met the standard for disqualification (repeated or deliberate failure to comply with applicable requirements) could potentially avoid disqualification and continue to be eligible to receive investigational products if they could provide FDA with adequate assurances of future compliance with requirements applicable to the use of investigational drugs and biologics. The provisions for adequate assurances are no longer in the regulations.